S

    Seres Therapeutics Inc (MCRB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.91
    -0.20 (-3.91%)

    Market Cap: $51.33M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(22/40)
    Avg Surprise
    -355.24%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.00
    Range$-1.34 - $-0.67
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-2.37-135.8%
    60d ago$-2.37-135.8%
    30d ago$-1.64-62.7%
    7d ago$-1.64-62.7%
    Current$-1.00
    Revenue Consensus
    $6M
    Range$200000 - $13M
    2 analysts
    Dec 31, 2026
    EPS Consensus$1.55
    Range$0.71 - $2.40
    2 analysts
    Revenue Consensus
    $7M
    Range$-5029000 - $20M
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.55---
    Sep 26EST
    		-$-1.00---
    Jun 26
    		$-1.50$-2.07+27.54%Beat+33.9%
    Mar 26
    		$-2.08$-1.88-10.64%Miss+7.1%
    Dec 25
    		$-1.76$-1.60-10.00%Miss-1500.0%
    Sep 25
    		$0.94$0.05+1780.00%Beat+114.2%
    Jun 25
    		$-2.27$-2.27+0.00%Beat+48.4%
    Mar 25
    		$-2.24$1.97-213.71%Miss+58.5%
    Dec 24
    		$-0.11$-0.20+44.81%Beat+65.6%
    Sep 24
    		$-6.60$-0.04-16400.00%Miss+10.8%
    Jun 24
    		$-4.40$-5.91+25.55%Beat-161.1%
    Mar 24
    		$-5.40$-7.25+25.52%Beat+52.6%
    Dec 23
    		$-0.32$-0.50+36.00%Beat+40.7%
    Sep 23
    		$-7.40$-10.65+30.52%Beat+24.5%
    Jun 23
    		$7.20$10.97-34.37%Miss+151.4%
    Mar 23
    		$-11.40$-10.85-5.07%Miss+6.6%
    Dec 22
    		$-0.54$-0.46-17.39%Miss-3.8%
    Sep 22
    		$-9.80$-9.44-3.81%Miss-168.1%
    Jun 22
    		$-14.00$-12.30-13.82%Miss-32.1%
    Mar 22
    		$-12.20$-10.04-21.51%Miss-56.4%
    Dec 21
    		$-0.52$-0.44-18.18%Miss-126.1%
    Sep 21
    		$14.40$-3.46+516.18%Beat+300.0%
    Jun 21
    		$-10.60$-7.63-38.93%Miss-89.3%
    Mar 21
    		$-7.80$-6.30-23.81%Miss-2685.7%
    Dec 20
    		$-0.23$-0.28+17.86%Beat+95.4%
    Sep 20
    		$-7.20$-5.00-44.00%Miss-56.5%
    Jun 20
    		$-5.60$-5.16-8.53%Miss-16.7%
    Mar 20
    		$-0.28$-0.28+0.00%Beat+97.5%
    Dec 19
    		$-5.00$-5.27+5.12%Beat-861.5%
    Sep 19
    		$-4.60$-5.27+12.71%Beat+57.4%
    Jun 19
    		$-4.80N/A+53.62%Beat+64.7%
    Mar 19
    		$-11.13$-9.20-20.98%Miss+19.3%
    Dec 18
    		$-0.52$-0.50-4.00%Miss+27.8%
    Sep 18
    		$-10.80$-10.92+1.10%Beat-217.6%
    Jun 18
    		$-13.60$-14.00+2.86%Beat+1.4%
    Mar 18
    		$-13.80$-15.25+9.51%Beat-9.5%
    Dec 17
    		$-0.72$-0.75+4.00%Beat-14.3%
    Sep 17
    		$-3.40N/A+65.66%Beat+63.0%
    Jun 17
    		$-13.80$-12.76-8.15%Miss-
    Mar 17
    		$-12.60$-13.13+4.04%Beat-
    Dec 16
    		$-0.63$-0.72+12.50%Beat-
    Sep 16
    		$-9.20$-10.46+12.05%Beat-

    Key Metrics

    Valuation
    P/E Ratio-1.12EV/EBITDA3.65x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-2101.00%
    ROE-66.60%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio2.11xQuick Ratio2.11x
    Trading Statistics
    Beta0.21Avg Volume64.01K
    52-Week High$29.9852-Week Low$4.32

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.75
    SMA 20$4.77
    SMA 50$5.57
    SMA 200$10.00
    EMA 10$4.83
    EMA 20$4.87
    EMA 50$5.46
    EMA 200$8.82

    MACD

    Line: -0.14Signal: -0.24Hist: 0.11

    ADX

    ADX: 20.6+DI: 19.1-DI: 12.1

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down64.0
    PSAR$4.38

    Bollinger Bands

    Upper Band$5.25
    Lower Band$4.29
    %B Position2004%(Upper)
    Band Width0.65

    RSI (14-Day)

    Neutral
    48.5

    Momentum Oscillators

    Stoch %K80.8
    Stoch %D74.4
    Williams %R-28.7
    ROC (10d)8.9%
    Momentum0.40
    CCI (20d)65.8
    MFI (14d)45.3

    Volatility Measures

    ATR (14d)$0.35(7.1%)
    StdDev (20d)0.24
    Hist Vol68.1%(High)

    Volume Flow

    VWAP$4.97
    OBV-8.0M
    AD Line16.1B
    CMF (20d)-0.153

    Volume Metrics

    Avg Vol (20d)65.7K
    Vol Ratio0.7x
    VWMA (20d)$4.77

    Pivot Points

    R3$5.57
    R2$5.36
    R1$5.23
    Pivot Point$5.02
    S1$4.89
    S2$4.68
    S3$4.55

    Advanced Oscillators

    TSI-11.13
    Ultimate Osc52.8
    KST-123.29

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$736,000$358,000$438,000$351,000$0$0$5.96M$0$0$0$-125,951,000$0
    Cost of Revenue$0$0$-13,805,000$0$0$0$5.13M$0$0$0$4.05M$0
    Gross Profit$736,000$358,000$438,000$351,000$0$0$-5,128,000$0$0$0$-125,951,000$0
    Operating Expenses$22.01M$21.27M$19.82M$22.83M$24.88M$27.24M$28.84M$29.17M$28.87M$34.44M$3.52M$44.59M
    R&D$9.14M$13.20M$11.68M$12.62M$12.94M$11.82M$12.84M$16.46M$15.81M$19.49M$1.68M$25.15M
    SG&A$7.06M$8.07M$7.54M$9.48M$10.25M$11.89M$12.46M$12.71M$13.06M$14.94M$7.55M$19.43M
    Operating Income$-21,273,000$-20,907,000$-19,377,000$-22,477,000$-24,881,000$-27,236,000$-28,836,000$-29,170,000$-28,871,000$-34,438,000$-129,467,000$-44,586,000
    Interest Income$181,000$325,000$445,000$618,000$546,000$618,000$437,000$652,000$1.23M$1.65M$1.97M$2.57M
    Interest Expense$0$0$0$0$0$0$0$21.86M$0$618,000$-2,667,000$0
    Income Before Tax$4.58M$-19,913,000$-15,335,000$8.20M$-19,855,000$32.68M$-15,637,000$-51,035,000$-26,196,000$-32,903,000$-124,493,000$-41,015,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$4.58M$-19,913,000$-15,335,000$8.20M$-19,855,000$32.68M$-15,637,000$88.78M$-32,870,000$-40,133,000$-41,248,000$-47,854,000
    EBITDA$5.07M$-19,457,000$-14,826,000$8.63M$-19,342,000$33.14M$-15,607,000$-49,820,000$-25,521,000$-31,909,000$-127,090,000$-41,510,000
    EBIT$4.40M$-20,238,000$-15,780,000$7.59M$-20,401,000$32.06M$-16,692,000$-51,687,000$-27,426,000$-33,933,000$-129,131,000$-43,587,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MCRB

    News

    Seres Therapeutics, Inc. SEC Filing (Aug 24, 2026)

    This article reports on an SEC filing by Seres Therapeutics, Inc. (MCRB), detailing the effectiveness of an S-3 shelf registration statement on August 21, 2026. The filing's impact and sentiment are noted as neutral. The report also provides an overview of Seres Therapeutics' stock performance, recent news, and other SEC filings.

    Stock Titan•8/24/26•
    Neutral

    Seres Therapeutics (MCRB) director sale tied to RSU tax plan

    Seres Therapeutics director Eric D. Shaff reported the vesting of 722 restricted stock units (RSUs) into common shares on August 15, 2026. Two days later, on August 17, 2026, Shaff sold 263 common shares at $4.55 each under a pre-arranged Rule 10b5-1 trading plan. This sale was explicitly made to cover tax obligations incurred from the RSU vesting.

    Stock Titan•8/19/26•
    Neutral

    Seres Therapeutics director Eric Shaff sells $1,196 in shares

    Seres Therapeutics director Eric Shaff sold 263 shares for $1,196 to cover taxes on vesting restricted stock units. This transaction occurred as the stock trades near its 52-week low, though InvestingPro analysis suggests it is undervalued with a fair value of $5.33. The company also announced positive trial results for SER-155 and secured $25 million from Nestlé Health Science, extending its cash runway.

    Investing.com•8/19/26•
    Neutral

    Seres Therapeutics director Eric Shaff sells $1,196 in shares

    Seres Therapeutics director Eric Shaff sold 263 shares of company stock worth $1,196 to cover taxes from vesting restricted stock units. This transaction occurred amidst the stock trading near its 52-week low. The company recently reported positive results for its experimental treatment SER-155 and secured $25 million from Nestlé Health Science to extend its cash runway.

    Investing.com•8/19/26•
    Neutral

    Seres Therapeutics director Eric Shaff sells $1,196 in shares By Investing.com

    Eric D. Shaff, a director at Seres Therapeutics, sold 263 shares of the company's common stock for $1,196 to cover taxes related to vested restricted stock units. This transaction occurred while the stock is near its 52-week low. The company recently reported promising results from a trial for its experimental treatment SER-155 and secured $25 million from Nestlé Health Science, with H.C. Wainwright initiating coverage with a "Buy" rating.

    Investing.com South Africa•8/18/26•
    Neutral

    Frequently Asked Questions About MCRB

    Does MCRB pay dividends?
    Seres Therapeutics Inc (MCRB) does not currently pay a regular dividend.
    What is MCRB's market cap?
    Seres Therapeutics Inc (MCRB) has a market capitalization of $51.33M with a current stock price of $4.91.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In